Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (821) 821
female (655) 655
index medicus (529) 529
bridged-ring compounds - administration & dosage (523) 523
animals (503) 503
male (469) 469
oncology (400) 400
middle aged (396) 396
taxoids - administration & dosage (345) 345
adult (334) 334
aged (331) 331
antineoplastic combined chemotherapy protocols - therapeutic use (317) 317
bridged-ring compounds - pharmacology (308) 308
bridged-ring compounds - therapeutic use (288) 288
breast neoplasms - drug therapy (281) 281
rats (258) 258
chemotherapy (254) 254
pharmacology & pharmacy (216) 216
cancer (210) 210
mice (204) 204
treatment outcome (188) 188
breast neoplasms - pathology (178) 178
paclitaxel (173) 173
breast cancer (167) 167
monoterpenes (140) 140
taxoids - therapeutic use (134) 134
docetaxel (132) 132
dose-response relationship, drug (129) 129
taxoids (128) 128
anthracyclines - administration & dosage (115) 115
antineoplastic agents - therapeutic use (115) 115
administration, oral (114) 114
bridged-ring compounds - adverse effects (112) 112
retrospective studies (107) 107
neoplasm staging (105) 105
disease-free survival (103) 103
bridged-ring compounds - chemistry (99) 99
analysis (97) 97
paeoniflorin (96) 96
time factors (96) 96
chemotherapy, adjuvant (95) 95
aged, 80 and over (93) 93
drug administration schedule (92) 92
care and treatment (91) 91
deoxycytidine - analogs & derivatives (90) 90
rats, sprague-dawley (90) 90
therapy (90) 90
antineoplastic combined chemotherapy protocols - adverse effects (87) 87
medicine & public health (86) 86
prognosis (85) 85
taxoids - adverse effects (85) 85
drug resistance, neoplasm (83) 83
survival (82) 82
taxane (82) 82
carcinoma (80) 80
trial (80) 80
antineoplastic agents - administration & dosage (79) 79
research (79) 79
bridged-ring compounds - pharmacokinetics (78) 78
deoxycytidine - administration & dosage (76) 76
neoadjuvant therapy (74) 74
neoplasm metastasis (73) 73
ovarian neoplasms - drug therapy (73) 73
hematology, oncology and palliative medicine (72) 72
survival rate (71) 71
fluorouracil - administration & dosage (69) 69
antineoplastic combined chemotherapy protocols - administration & dosage (66) 66
cisplatin - administration & dosage (66) 66
glucosides - pharmacology (66) 66
survival analysis (66) 66
anthracyclines (65) 65
bridged bicyclo compounds - pharmacology (63) 63
cisplatin (62) 62
lung neoplasms - drug therapy (62) 62
paclitaxel - administration & dosage (59) 59
ramipril (59) 59
obstetrics & gynecology (57) 57
article (56) 56
bridged-ring compounds - metabolism (56) 56
chemistry, medicinal (56) 56
expression (56) 56
pharmacokinetics (56) 56
benzoates - pharmacology (55) 55
metastasis (54) 54
follow-up studies (53) 53
ovarian cancer (53) 53
clinical trials as topic (52) 52
anthracyclines - therapeutic use (51) 51
biochemistry & molecular biology (51) 51
breast neoplasms - mortality (51) 51
capecitabine (51) 51
health aspects (51) 51
taxoids - pharmacology (51) 51
tumors (51) 51
antineoplastic agents - adverse effects (50) 50
paeonia - chemistry (49) 49
phase-ii (49) 49
breast neoplasms - metabolism (48) 48
carcinoma, non-small-cell lung - drug therapy (48) 48
cell line, tumor (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1118) 1118
Japanese (40) 40
Chinese (38) 38
Russian (19) 19
German (8) 8
French (6) 6
Italian (5) 5
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Toxicity of cucurbit[7]uril and cucurbit[8]uril: An exploratory in vitro and in vivo study
by Uzunova, Vanya D and Cullinane, Carleen and Brix, Klaudia and Nau, Werner M and Day, Anthony I
Organic and Biomolecular Chemistry, ISSN 1477-0520, 2010, Volume 8, Issue 9, pp. 2037 - 2042
Cucurbit[n]urils (CB[n]) are potential stabilizing, solubilizing, activating, and delivering agents for drugs. The toxicity of the macrocyclic host molecules... 
Cell Survival - drug effects | Cricetinae | Cricetulus | Cells, Cultured | Imidazoles - chemistry | Imidazoles - administration & dosage | Bridged-Ring Compounds - metabolism | Structure-Activity Relationship | Dose-Response Relationship, Drug | Animals | Bridged-Ring Compounds - chemistry | Female | Bridged-Ring Compounds - toxicity | Imidazoles - toxicity | Mice | Mice, Inbred BALB C | Drug Evaluation, Preclinical | Bridged-Ring Compounds - administration & dosage | CHO Cells | Imidazoles - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group
by Pierre Blanchard and Jean Bourhis and Benjamin Lacas and Marshall R. Posner and Jan B. Vermorken and Juan J. Cruz Hernandez and Abderrahmane Bourredjem and Gilles Calais and Adriano Paccagnella and Ricardo Hitt and Jean-Pierre Pignon and Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group
Journal of Clinical Oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2854 - 2860
Purpose Cisplatin plus fluorouracil (PF) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF)... 
TRIAL | 5-FLUOROURACIL | ONCOLOGY | LARYNX PRESERVATION | PHASE-II | CHEMORADIOTHERAPY | DOCETAXEL | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Induction Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Cisplatin - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Bridged-Ring Compounds - adverse effects | Bridged-Ring Compounds - administration & dosage | Taxoids - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
by Ian E. Krop and Patricia LoRusso and Kathy D. Miller and Shanu Modi and Denise Yardley and Gladys Rodriguez and Ellie Guardino and Michael Lu and Maoxia Zheng and Sandhya Girish and Lukas Amler and Eric P. Winer and Hope S. Rugo
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 26, pp. 3234 - 3241
Purpose To determine whether the antibody-drug conjugate trastuzumab emtansine (T-DM1), which combines human epidermal growth factor receptor 2 (HER2)... 
ADJUVANT CHEMOTHERAPY | TRIAL | 1ST-LINE TREATMENT | MAYTANSINE | GENE | ONCOLOGY | RESISTANCE | OVARIAN-CANCER | COMBINATION | PERTUZUMAB | PLUS | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Male | Antineoplastic Agents - therapeutic use | Breast Neoplasms - metabolism | Neoplasm Metastasis | Anthracyclines - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Adult | Female | Quinazolines - administration & dosage | Molecular Targeted Therapy - methods | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Immunotoxins - therapeutic use | Breast Neoplasms - pathology | Aged | Bridged-Ring Compounds - administration & dosage | Deoxycytidine - analogs & derivatives | Trastuzumab | Quinazolines - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study
by Perez, Edith A and Barrios, Carlos and Eiermann, Wolfgang and Toi, Masakazu and Im, Young-Hyuck and Conte, Pierfranco and Martin, Miguel and Pienkowski, Tadeusz and Pivot, Xavier and Burris, Howard and Petersen, Jennifer A and Stanze, Sven and Strasak, Alexander and Patre, Monika and Ellis, Paul
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 2, pp. 141 - 148
Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) -targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an... 
TRIAL | CAPECITABINE | THERAPY | ONCOLOGY | COMBINATION | DOCETAXEL | PACLITAXEL | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Maytansine - analogs & derivatives | Humans | Middle Aged | Drug Tolerance | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Trastuzumab - administration & dosage | Random Allocation | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Breast Neoplasms - chemistry | Maytansine - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
by Twelves, Chris and Cortes, Javier and Vahdat, Linda and Olivo, Martin and He, Yi and Kaufman, Peter A and Awada, Ahmad
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2014, Volume 148, Issue 3, pp. 553 - 561
Data from two phase 3 studies of eribulin were pooled in analyses initially requested by the European Medicines Agency to assess whether specific patient... 
Oncology | Metastatic breast cancer | Medicine & Public Health | Pooled analysis | Eribulin mesylate | Halaven | ONCOLOGY | SAFETY | DOXORUBICIN | FOLLOW-UP | PATTERNS | DOCETAXEL | CHEMOTHERAPY | RECHALLENGE | Anthracyclines - adverse effects | Receptor, ErbB-2 - genetics | Capecitabine | Humans | Middle Aged | Furans - adverse effects | Neoplasm Metastasis | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Ketones - adverse effects | Taxoids - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Ketones - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Bridged-Ring Compounds - adverse effects | Aged | Bridged-Ring Compounds - administration & dosage | Deoxycytidine - analogs & derivatives | Furans - administration & dosage | Women | Care and treatment | Anthracyclines | Chemotherapy | Analysis | Oncology, Experimental | Breast cancer | Metastasis | Research | Cancer | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
by Edith A. Perez and Vera J. Suman and Nancy E. Davidson and Julie R. Gralow and Peter A. Kaufman and Daniel W. Visscher and Beiyun Chen and James N. Ingle and Shaker R. Dakhil and JoAnne Zujewski and Alvaro Moreno-Aspitia and Thomas M. Pisansky and Robert B. Jenkins
Journal of Clinical Oncology, ISSN 0732-183X, 12/2011, Volume 29, Issue 34, pp. 4491 - 4497
Purpose NCCTG (North Central Cancer Treatment Group) N9831 is the only randomized phase III trial evaluating trastuzumab added sequentially or used... 
TRIAL | OVEREXPRESSION | ONCOLOGY | DOXORUBICIN | FOLLOW-UP | PROGNOSTIC-SIGNIFICANCE | COMBINATION | N9831 | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - adverse effects | Adolescent | Adult | Female | Bridged-Ring Compounds - administration & dosage | Trastuzumab | Original Reports | Bios3 | Bc6 | Psc12 | Bc5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis
by ter Veer, Emil and Mohammad, Nadia Haj and Valkenhoef , van, Gert and Ngai, Lok Lam and Mali, Rosa M. A and Anderegg, Maarten C and van Oijen, Martijn G. H and van Laarhoven, Hanneke W. M
Jnci-Journal of the national cancer institute, ISSN 0027-8874, 10/2016, Volume 108, Issue 10, p. djw166
Background: A globally accepted standard first-line chemotherapy regimen in advanced esophagogastric cancer (AEGC) is not clearly established. We conducted a... 
JUNCTION ADENOCARCINOMA | GASTROESOPHAGEAL ADENOCARCINOMA | NAIVE PATIENTS | ONCOLOGY | RANDOMIZED PHASE-II | FEDERATION-FRANCOPHONE | EUROPEAN ORGANIZATION | ADVANCED GASTRIC-CANCER | DOUBLE-BLIND | FOLINIC ACID | FLUOROURACIL PLUS CISPLATIN | Capecitabine - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Survival Rate | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Cisplatin - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Esophagogastric Junction | Taxoids - administration & dosage | Organoplatinum Compounds - administration & dosage | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Esophageal Neoplasms - mortality | Tegafur - administration & dosage | Camptothecin - administration & dosage | Methotrexate - administration & dosage | Network Meta-Analysis | Bridged-Ring Compounds - administration & dosage | Esophageal Neoplasms - drug therapy | Drug Combinations | Camptothecin - analogs & derivatives | Dose-response relationship (Biochemistry) | Chemotherapy | Patient outcomes | Drug therapy | Stomach cancer | Methods | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
by Chang, Suk-Joon and Hodeib, Melissa and Chang, Jenny and Bristow, Robert E
Gynecologic Oncology, ISSN 0090-8258, 2013, Volume 130, Issue 3, pp. 493 - 498
Abstract Objective To quantify the impact of complete cytoreduction to no gross residual disease on overall survival among patients with advanced-stage ovarian... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Complete cytoreduction | Advanced ovarian cancer | Residual disease | INTRAVENOUS CISPLATIN PLUS | 1ST-LINE TREATMENT | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | PROGNOSTIC-FACTORS | SURGICAL CYTOREDUCTION | RANDOMIZED-TRIAL | OBSTETRICS & GYNECOLOGY | PHASE-III TRIAL | DES CANCERS | ONCOLOGY | INTRAPERITONEAL CISPLATIN | Carcinoma - drug therapy | Carcinoma - surgery | Humans | Ovarian Neoplasms - pathology | Neoplasm, Residual | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Female | Chemotherapy, Adjuvant | Platinum Compounds - administration & dosage | Carcinoma - pathology | Neoplasm Staging | Bridged-Ring Compounds - administration & dosage | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Analysis | Ovarian cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
by Vergote, I and Armstrong, D and Scambia, G and Teneriello, M and Sehouli, J and Schweizer, C and Weil, SC and Bamias, A and Fujiwara, K and Ochiai, K and Poole, C and Gorbunova, V and Wang, WQ and O'Shannessy, D and Herzog, TJ
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2016, Volume 34, Issue 19, pp. 2271 - 2271
Purpose Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-alpha, which is highly expressed in ovarian carcinoma and largely absent... 
CA-125 | CA125 | MONOCLONAL-ANTIBODY | ONCOLOGY | FOLATE RECEPTOR-ALPHA | Antibodies, Monoclonal, Humanized - adverse effects | CA-125 Antigen - blood | Double-Blind Method | Humans | Middle Aged | Carboplatin - administration & dosage | Ovarian Neoplasms - mortality | Carboplatin - adverse effects | Taxoids - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Bridged-Ring Compounds - adverse effects | Female | Aged | Bridged-Ring Compounds - administration & dosage | Ovarian Neoplasms - drug therapy | Taxoids - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
by Anas Younes and Jorge Romaguera and Michelle Fanale and Peter McLaughlin and Frederick Hagemeister and Amanda Copeland and Sattva Neelapu and Larry Kwak and Jatin Shah and Silvana de Castro Faria and Stefan Hart and Jeanette Wood and Ramesh Jayaraman and Kantharaj Ethirajulu and Joy Zhu
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 33, pp. 4161 - 4167
Purpose The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) pathway plays an important role in the pathogenesis of hematologic... 
CYTOKINES | METHYLATION | ONCOLOGY | PATHWAY | NON-HODGKIN-LYMPHOMA | CELL-PROLIFERATION | JAK/STAT | SOCS-1 | JAK2 | EXPRESSION | RUXOLITINIB | Recurrence | Administration, Oral | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Young Adult | Protein Kinase Inhibitors - administration & dosage | Lymphoma - drug therapy | Janus Kinase 2 - metabolism | Pyrimidines - adverse effects | Aged, 80 and over | Lymphoma - enzymology | Adult | Bridged-Ring Compounds - adverse effects | Female | Aged | Bridged-Ring Compounds - administration & dosage | Janus Kinase 2 - antagonists & inhibitors | Cohort Studies | Index Medicus | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text PH responsive supramolecular prodrug micelles based on cucurbit[8]uril for intracellular drug delivery
by Wang, Yin and Li, Dandan and Wang, Haibo and Chen, Yangjun and Han, Haijie and Jin, Qiao and Ji, Jian
Chemical Communications, ISSN 1359-7345, 08/2014, Volume 50, Issue 66, pp. 9390 - 9392
The first attempt of constructing pH responsive supramolecular prodrug micelles based on cucurbit[8]uril is reported. The obtained prodrug micelles are found... 
NANOPARTICLES | DOXORUBICIN | PROGRESS | FABRICATION | RELEASE | CHEMISTRY, MULTIDISCIPLINARY | WATER | Prodrugs - administration & dosage | Microscopy, Electron, Transmission | Antibiotics, Antineoplastic - pharmacology | Imidazoles - chemistry | Imidazoles - administration & dosage | Prodrugs - chemistry | Drug Carriers | Antibiotics, Antineoplastic - administration & dosage | Bridged-Ring Compounds - chemistry | Proton Magnetic Resonance Spectroscopy | Micelles | Bridged-Ring Compounds - administration & dosage | Doxorubicin - pharmacology | Doxorubicin - administration & dosage | Hydrogen-Ion Concentration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
by Krop, Ian E, Dr and Kim, Sung-Bae, Prof and Martin, Antonio Gonzalez, MD and LoRusso, Patricia M, Prof and Ferrero, Jean-Marc, MD and Badovinac-Crnjevic, Tanja, MD and Hoersch, Silke, MSc and Smitt, Melanie, MD and Wildiers, Hans, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 743 - 754
Summary Background In the randomised, parallel assignment, open-label, phase 3 TH3RESA study, progression-free survival was significantly longer with... 
Hematology, Oncology and Palliative Medicine | RESISTANT | WOMEN | THERAPY | EFFICACY | ONCOLOGY | SAFETY | BRAIN METASTASES | T-DM1 | LAPATINIB PLUS CAPECITABINE | Chemotherapy-Induced Febrile Neutropenia - etiology | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Practice Patterns, Physicians | Diarrhea - chemically induced | Early Termination of Clinical Trials | Breast Neoplasms - chemistry | Neoplasm Metastasis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Neutropenia - chemically induced | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Retreatment | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Breast Neoplasms, Male - pathology | Hemorrhage - chemically induced | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Hospitals | Physicians | Patient outcomes | Analysis | Breast cancer | Metastasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Anthracyclines in early breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
by Blum, Joanne L and Flynn, Patrick J and Yothers, Greg and Asmar, Lina and Geyer, Charles E and Jacobs, Samuel A and Robert, Nicholas J and Hopkins, Judith O and O’Shaughnessy, Joyce A and Dang, Chau T and Gómez, Henry Leonidas and Fehrenbacher, Louis and Vukelja, Svetislava J and Lyss, Alan P and Paul, Devchand and Brufsky, Adam M and Jeong, Jong-Hyeon and Colangelo, Linda H and Swain, Sandra M and Mamounas, Eleftherios P and Jones, Stephen E and Wolmark, Norman
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 23, pp. 2647 - 2655
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC... 
ADJUVANT CHEMOTHERAPY | ONCOLOGY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | FOLLOW-UP | REGIMEN | DOCETAXEL | PACLITAXEL | Cyclophosphamide - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Carcinoma, Ductal, Breast - chemistry | Breast Neoplasms - therapy | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Anthracyclines - administration & dosage | Carcinoma, Intraductal, Noninfiltrating - therapy | Mastectomy | Female | Chemotherapy, Adjuvant | Carcinoma, Ductal, Breast - secondary | Doxorubicin - administration & dosage | Lymphatic Metastasis | Carcinoma, Intraductal, Noninfiltrating - chemistry | Carcinoma, Ductal, Breast - therapy | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | ORIGINAL REPORTS | Chemotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Trastuzumab-containing regimens for metastatic breast cancer
by Balduzzi, Sara and Balduzzi, Sara and Mantarro, Stefania and Mantarro, Stefania and Guarneri, Valentina and Guarneri, Valentina and Tagliabue, Ludovica and Tagliabue, Ludovica and Pistotti, Vanna and Pistotti, Vanna and Moja, Lorenzo and Moja, Lorenzo and D'Amico, Roberto and D'Amico, Roberto
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 6, Issue 6, pp. CD006242 - CD006242
Background Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive)... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | NEU ONCOGENE | CLINICAL-TRIALS | RECEPTOR | MONOCLONAL-ANTIBODY | CHEMOTHERAPY PLUS TRASTUZUMAB | QUALITY-OF-LIFE | COMBINATION | DISEASE PROGRESSION | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Agents - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Anthracyclines - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Female | Quinazolines - administration & dosage | Lapatinib | Aromatase Inhibitors - therapeutic use | Bridged-Ring Compounds - administration & dosage | Trastuzumab | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
by Kleckner, Ian R and Kamen, Charles and Gewandter, Jennifer S and Mohile, Nimish A and Heckler, Charles E and Culakova, Eva and Fung, Chunkit and Janelsins, Michelle C and Asare, Matthew and Lin, Po-Ju and Reddy, Pavan S and Giguere, Jeffrey and Berenberg, Jeffrey and Kesler, Shelli R and Mustian, Karen M
Supportive Care in Cancer, ISSN 0941-4355, 4/2018, Volume 26, Issue 4, pp. 1019 - 1028
Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy... 
Pain Medicine | Nursing | Rehabilitation Medicine | Exercise | Medicine & Public Health | Nursing Research | Oncology | CIPN | Neuropathy | MANAGEMENT | PREVENTION | PREVALENCE | CANCER SURVIVORS | PAIN | ONCOLOGY | PREDICTORS | CLINICAL-TRIALS | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | PHYSICAL-ACTIVITY | QUALITY-OF-LIFE | OUTCOMES | Exercise Therapy - methods | Peripheral Nervous System Diseases - chemically induced | Humans | Middle Aged | Vinca Alkaloids - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Peripheral Nervous System Diseases - therapy | Male | Peripheral Nervous System Diseases - physiopathology | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Taxoids - administration & dosage | Organoplatinum Compounds - administration & dosage | Vinca Alkaloids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Bridged-Ring Compounds - adverse effects | Female | Neoplasm Staging | Neoplasms - pathology | Bridged-Ring Compounds - administration & dosage | Organoplatinum Compounds - adverse effects | Taxoids - adverse effects | Alkaloids | Chemotherapy | Health aspects | Analysis | Mortality | Cancer | Clinical trials | Breast cancer | Peripheral neuropathy | Index Medicus | exercise | neuropathy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights